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BACKGROUND
Heart failure is associated with activation of thrombin-related pathways, which 
predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a fac-
tor Xa inhibitor, could reduce thrombin generation and improve outcomes for pa-
tients with worsening chronic heart failure and underlying coronary artery disease.
METHODS
In this double-blind, randomized trial, 5022 patients who had chronic heart fail-
ure, a left ventricular ejection fraction of 40% or less, coronary artery disease, and 
elevated plasma concentrations of natriuretic peptides and who did not have atrial 
fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg 
twice daily or placebo in addition to standard care after treatment for an episode 
of worsening heart failure. The primary efficacy outcome was the composite of 
death from any cause, myocardial infarction, or stroke. The principal safety out-
come was fatal bleeding or bleeding into a critical space with a potential for caus-
ing permanent disability.
RESULTS
Over a median follow-up period of 21.1 months, the primary end point occurred 
in 626 (25.0%) of 2507 patients assigned to rivaroxaban and in 658 (26.2%) of 2515 
patients assigned to placebo (hazard ratio, 0.94; 95% confidence interval [CI], 0.84 
to 1.05; P = 0.27). No significant difference in all-cause mortality was noted between 
the rivaroxaban group and the placebo group (21.8% and 22.1%, respectively; hazard 
ratio, 0.98; 95% CI, 0.87 to 1.10). The principal safety outcome occurred in 18 pa-
tients who took rivaroxaban and in 23 who took placebo (hazard ratio, 0.80; 95% CI, 
0.43 to 1.49; P = 0.48).
CONCLUSIONS
Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly 
lower rate of death, myocardial infarction, or stroke than placebo among patients 
with worsening chronic heart failure, reduced left ventricular ejection fraction, coro-
nary artery disease, and no atrial fibrillation. (Funded by Janssen Research and 
Development; COMMANDER HF ClinicalTrials.gov number, NCT01877915.)
A BS TR AC T
Rivaroxaban in Patients with Heart Failure, 
Sinus Rhythm, and Coronary Disease
Faiez Zannad, M.D., Ph.D., Stefan D. Anker, M.D., Ph.D., William M. Byra, M.D., 
John G.F. Cleland, M.D., Min Fu, Ph.D., Mihai Gheorghiade, M.D.,* 
Carolyn S.P. Lam, M.D., Ph.D., Mandeep R. Mehra, M.D., James D. Neaton, Ph.D., 
Christopher C. Nessel, M.D., Theodore E. Spiro, M.D., 
Dirk J. van Veldhuisen, M.D., Ph.D., and Barry Greenberg, M.D.,  
for the COMMANDER HF Investigators† 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on September 5, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 2
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
A fter an episode of worsening chronic heart failure, rates of readmis-sion to the hospital and of death are high, 
especially in the first few months.1,2 Activation 
of thrombin-related pathways may contribute to 
disease progression by inducing inflammation, 
endothelial dysfunction, and arterial and venous 
thrombosis.3 However, warfarin has not improved 
outcomes among patients with heart failure and 
reduced ejection fraction who are in sinus rhythm, 
and patients receiving warfarin have been found 
to have higher rates of bleeding complications 
than patients who receive antiplatelet agents or no 
antithrombotic therapy.4-7
Rivaroxaban is an oral direct factor Xa inhibi-
tor that reduces thrombin generation.8,9 In doses 
of 10 to 20 mg daily, this agent is approved for a 
variety of indications, including the treatment 
and prevention of venous thromboembolism and 
the prevention of stroke or systemic embolism in 
patients with atrial fibrillation.10-12 Lower doses 
of rivaroxaban (e.g., 2.5 mg twice daily), in com-
bination with antiplatelet agents, have been found 
to reduce the risk of death from cardiovascular 
causes, myocardial infarction, and stroke in pa-
tients with acute coronary syndromes or stable 
coronary artery disease.13,14 We designed a trial to 
test the hypothesis that rivaroxaban at a dose of 
2.5 mg twice daily, added to background antiplate-
let therapy, would be associated with lower rates 
of death and cardiovascular events than placebo 
among patients with recent worsening of chron-
ic heart failure, reduced ejection fraction, coronary 
artery disease, and no atrial fibrillation.
Me thods
Trial Design and Oversight
The COMMANDER HF trial (A Study to Assess the 
Effectiveness and Safety of Rivaroxaban in Reduc-
ing the Risk of Death, Myocardial Infarction, or 
Stroke in Participants with Heart Failure and Coro-
nary Artery Disease Following an Episode of 
Decompensated Heart Failure) was a multicenter, 
randomized, double-blind, placebo-controlled, 
event-driven trial.15 The sponsor was Janssen Re-
search and Development. The trial was conducted 
and reported in accordance with the protocol and 
the statistical analysis plan, both of which are 
available with the full text of this article at NEJM 
.org. The pertinent national regulatory authorities 
and ethics committees at participating centers ap-
proved the protocol. An international steering 
committee, made up of members from academic 
institutions and one member from Janssen, de-
signed the trial, were responsible for overseeing 
the conduct of the trial, retained the ability to 
present the data, and made the decision to sub-
mit the manuscript for publication. The steering 
committee vouches for the accuracy and com-
pleteness of the data and all analyses and for the 
fidelity of the trial to the protocol.
The sponsor contracted with members of the 
steering committee, selected and contracted with 
the trial sites, provided the rivaroxaban and pla-
cebo, performed site monitoring and oversight, 
collected and managed the data, and performed 
the data analysis. The first draft was completed 
by the first and last authors, reviewed and revised 
by all authors, and supported by Janssen. An in-
dependent data and safety monitoring commit-
tee had complete access to unblinded data dur-
ing the conduct of the trial and were responsible 
for the safety of the enrolled patients as well as 
for the performance of a single, prespecified in-
terim analysis for efficacy.
Participants
We enrolled patients who had at least a 3-month 
history of chronic heart failure, a left ventricular 
ejection fraction of 40% or less, and coronary ar-
tery disease and who had been treated for an 
episode of worsening heart failure (i.e., the index 
event) within the previous 21 days. After the enroll-
ment of 1155 patients (23.0%), a protocol amend-
ment required patients to also have a plasma con-
centration of brain natriuretic peptide (BNP) that 
was at least 200 pg per milliliter or N-terminal 
pro–brain natriuretic peptide (NT-proBNP) that 
was at least 800 pg per milliliter measured at any 
time during the screening period before random-
ization.
Exclusion criteria were a high risk of bleeding, 
atrial fibrillation or another condition that re-
quired long-term anticoagulation, either acute 
myocardial infarction or surgical or percutane-
ous coronary artery intervention during the index 
event, an estimated glomerular filtration rate of 
less than 20 ml per minute per 1.73 m2, recent 
stroke or previous intracranial hemorrhage, or 
heart failure due to a cause other than coronary 
artery disease. Definitions of all the inclusion 
and exclusion criteria are provided in the Supple-
mentary Appendix, available at NEJM.org. Writ-
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ten informed consent was obtained from all the 
patients.
Randomization and Trial Regimen
Using an interactive Web response system and 
permuted blocks of four, we randomly assigned 
patients in a 1:1 ratio to receive 2.5 mg of rivar-
oxaban twice daily or matching placebo, within 
strata defined according to country. After random-
ization, patients were seen at week 4 and week 12 
and then every 12 weeks thereafter for assess-
ment of safety and to ascertain the occurrence of 
outcome events. Patients who temporarily discon-
tinued the trial regimen could restart it at any 
time, provided they continued to meet all the in-
clusion criteria and none of the exclusion criteria. 
All the patients were to receive standard care for 
heart failure and coronary artery disease as pre-
scribed by their treating physician. Single or dual 
antiplatelet therapy was allowed.
Outcomes
The primary efficacy outcome was the composite 
of death from any cause, myocardial infarction, 
or stroke. Secondary efficacy outcomes included 
death from cardiovascular causes, rehospitaliza-
tion for worsening heart failure, rehospitalization 
for cardiovascular events, and the composite of 
death from cardiovascular causes or rehospitaliza-
tion for worsening heart failure. Before unblind-
ing, the statistical analysis plan was amended to 
include an analysis of the composite of death 
from any cause or rehospitalization for worsening 
heart failure. Other efficacy outcomes included 
symptomatic deep-vein thrombosis or pulmonary 
embolism. The principal safety outcome was the 
composite of fatal bleeding or bleeding into a 
critical space with a potential for causing perma-
nent disability. Secondary safety outcomes includ-
ed bleeding events requiring hospitalization and 
clinically overt major bleeding events as defined 
by the International Society on Thrombosis and 
Haemostasis (ISTH) (i.e., associated with a de-
crease in hemoglobin level of ≥2 g per deciliter, 
transfusion of 2 or more units of packed red cells 
or whole blood, a critical site [intracranial, intra-
spinal, intraocular, pericardial, intraarticular, in-
tramuscular with compartment syndrome, or retro-
peritoneal], or a fatal outcome).
An independent clinical-events adjudication 
committee was not used in this trial because it 
was anticipated that the most common outcome 
would be death. In addition, outcomes were ascer-
tained by investigators using an extensive, dedi-
cated case-report form, with source-data verifica-
tion by the sponsor’s clinical operations team. A 
complete list of outcome-event definitions is pro-
vided in the Supplementary Appendix. Data on 
serious adverse events or any event leading to per-
manent discontinuation of rivaroxaban or pla-
cebo were also collected and classified with the 
use of the Medical Dictionary for Regulatory Ac-
tivities (MedDRA), version 20.1.
Sample Size and Interim Analysis
The original protocol specified 984 primary effi-
cacy outcomes for this event-driven trial. On the 
basis of a blinded review of accumulated data indi-
cating a lower event rate and higher rate of discon-
tinuation of the trial regimen than originally esti-
mated, several changes were made to the trial plan 
by the steering committee in November 2016. 
Follow-up was extended, and the target number of 
primary events was increased to 1200. The original 
goal of 5000 patients was retained. With an ex-
pected discontinuation rate of 13 per 100 person-
years, a total of 1200 events of the primary ef-
ficacy outcome was calculated to provide 80% 
power to detect a 20% lower hazard of the pri-
mary outcome in the rivaroxaban group than in 
the placebo group, with a two-sided type I error 
rate of 0.05.
An independent data and safety monitoring 
committee performed a single, prespecified in-
terim analysis to consider early termination of the 
trial for efficacy when 632 primary efficacy events 
had occurred. For this analysis, O’Brien–Fleming 
boundaries and the Lan–DeMets spending func-
tion were used.
Statistical Analysis
The trial groups were analyzed according to the 
intention-to-treat principle for all the efficacy out-
comes. A hierarchical analysis plan stipulated 
that if the primary efficacy outcome did not dif-
fer significantly between the trial groups, second-
ary efficacy outcomes would be reported without 
claims of statistical significance. Safety outcome 
comparisons were restricted to patients who took 
at least one dose of rivaroxaban or placebo. We 
used time-to-event methods, including the log-
rank test (stratified according to five geographic 
regions), Cox models, and Kaplan–Meier estimates 
of the cumulative risk. Data on vital status were 
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censored on March 5, 2018 (the global treatment 
end date of the trial), or the date of last known 
contact. For all efficacy and safety outcomes, es-
timated hazard ratios and 95% confidence inter-
vals are cited along with event rates per 100 per-
son-years. The proportional-hazards assumption 
was tested and confirmed for the primary out-
come by including an interaction term between 
the treatment indicator and log-transformed fol-
low-up time.
Heterogeneity of the treatment effect for the 
primary efficacy outcome was evaluated by as-
sessing treatment interactions across subgroups 
in expanded Cox models. Results for these analy-
ses should be interpreted with caution because 
there was no adjustment for type I error, and sta-
tistical power was limited.
R esult s
Participants and Follow-up
From September 2013 through October 2017, a 
total of 5022 patients were randomly assigned to 
receive rivaroxaban (2.5 mg twice daily) or match-
ing placebo at 628 sites in 32 countries (Fig. 1). 
The characteristics of the patients and therapies 
for heart failure and coronary artery disease were 
well balanced between the trial groups at baseline 
(Table 1, and Table S1 in the Supplementary Ap-
pendix).
Coronary artery disease was identified by the 
presence of at least one of the following charac-
teristics: previous myocardial infarction (75.7% of 
patients), angiographic evidence of at least 50% 
stenosis in one or more coronary arteries (59.4%), 
history of percutaneous coronary intervention 
(51.4%), history of coronary-artery bypass graft-
ing (19.8%), or pathologic Q waves on electrocar-
diography with corresponding wall-motion ab-
normalities (34.7%). The median ejection fraction 
was 34% (interquartile range, 28 to 38), 53% of 
patients were in New York Heart Association func-
tional class III or IV heart failure at baseline, and 
more than 50% of patients underwent randomiza-
tion within 5 days after discharge.
At baseline, almost all the patients (99.5%) were 
taking diuretics, 92.8% were taking angiotensin-
converting–enzyme inhibitors or angiotensin-
receptor blockers, 76.5% were taking mineralo-
corticoid-receptor antagonists, and 92.4% were 
taking beta-blockers. This pattern of guideline-
based therapy was maintained throughout the 
trial (Table S2 in the Supplementary Appendix). 
Aspirin, alone or in combination with a thieno-
pyridine, was taken by 93.1% of the patients, with 
34.8% taking dual antiplatelet therapy at baseline.
On the global treatment end date, data on vital 
status were available for 5013 patients (99.8%), 
and the median follow-up duration was 21.1 
months (interquartile range, 12.9 to 32.8). The 
rates of permanent discontinuation of the trial 
regimen before a primary efficacy event were 16.3 
and 13.6 per 100 person-years in the rivaroxaban 
and placebo groups, respectively. The reasons for 
discontinuation are provided in Table S3 in the 
Supplementary Appendix.
Primary Efficacy Outcome
The primary efficacy outcome occurred in 626 
patients (25.0%) assigned to rivaroxaban and 658 
patients (26.2%) assigned to placebo (hazard 
ratio, 0.94; 95% confidence interval [CI], 0.84 to 
1.05; P = 0.27) (Table 2). The Kaplan–Meier esti-
mates of the cumulative percentage of patients 
with this primary outcome were 13.2%, 24.1%, 
Figure 1. Randomization and Follow-up.
Three patients (one in the rivaroxaban group and two in the placebo group) 
underwent randomization twice; only the first randomization was counted. 
Patients were considered to have completed the trial if they died or were 
followed according to the visit schedule until the end-of-trial visit. “Had 
other reasons” primarily includes patients at sites in Ukraine and Turkey 
that were affected by local military action. Data on vital status were collect-
ed as of the global treatment end date (March 5, 2018) and included all 
sources allowed by local regulations.
5022 Patients underwent randomization
2507 Were assigned to receive
rivaroxaban
2515 Were assigned to receive
placebo
2453 Completed the study
54 Did not complete study
10 Were lost to follow-up
42 Withdrew consent
2 Had other reasons
2447 Completed the study
68 Did not complete study
9 Were lost to follow-up
55 Withdrew consent
4 Had other reasons
2503 Had known vital status
as of global treatment end date
4 Had unknown vital status
as of global treatment end date
2510 Had known vital status
as of global treatment end date
5 Had unknown vital status
as of global treatment end date
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Characteristic
Rivaroxaban 
(N = 2507)
Placebo 
(N = 2515)
Age — yr 66.5±10.1 66.3±10.3
Female sex — no. (%) 551 (22.0) 599 (23.8)
Race — no. (%)†
White 2063 (82.3) 2065 (82.1)
Black 29 (1.2) 36 (1.4)
Asian 362 (14.4) 365 (14.5)
Other 53 (2.1) 49 (1.9)
Region — no. (%)
Eastern Europe 1610 (64.2) 1614 (64.2)
North America 74 (3.0) 75 (3.0)
Asia-Pacific 367 (14.6) 366 (14.6)
Latin America 229 (9.1) 229 (9.1)
Western Europe or South Africa 227 (9.1) 231 (9.2)
Body-mass index‡ 27.6±5.1 27.8±5.3
eGFR — no. (%)
<30 ml/min/1.73 m2 81 (3.2) 82 (3.3)
30 to <60 ml/min/1.73 m2 884 (35.3) 898 (35.7)
60 to <90 ml/min/1.73 m2 1101 (43.9) 1137 (45.2)
≥90 ml/min/1.73 m2 441 (17.6) 398 (15.8)
Clinical features of heart failure
Median BNP level (IQR) — pg/ml§ 702.0 (403.4–1237.0) 695.5 (380.0–1266.3)
Median NT-proBNP level (IQR) — pg/ml§ 2840.0 (1537.0–6394.0) 2900.0 (1520.0–6270.5)
Median d-dimer level (IQR) — μg/liter 360 (215–680) 360 (215–650)
Median ejection fraction (IQR) — % 35 (28–38) 34 (27–38)
New York Heart Association classification — no. (%)
I 80 (3.2) 69 (2.7)
II 1122 (44.8) 1096 (43.6)
III 1208 (48.2) 1254 (49.9)
IV 96 (3.8) 96 (3.8)
Medical history — no. (%)
Myocardial infarction 1911 (76.2) 1892 (75.2)
Stroke 208 (8.3) 245 (9.7)
Diabetes 1024 (40.8) 1028 (40.9)
Hypertension 1897 (75.7) 1886 (75.0)
*  Plus–minus values are means ±SD. There were no significant differences between the groups with regard to any charac-
teristic. More details about the baseline characteristics are provided in Table S1 in the Supplementary Appendix. 
Percentages may not total 100 because of rounding. BNP denotes brain natriuretic peptide, eGFR estimated glomerular 
filtration rate, IQR interquartile range, and NT-proBNP N-terminal pro–brain natriuretic peptide.
†  Race was reported by the patient.
‡  Body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Data on natriuretic peptides were obtained after protocol amendment. Data on BNP were obtained for 965 patients, 
and data on NT-proBNP were obtained for 2862 patients.
Table 1. Characteristics of the Patients at Baseline.*
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and 31.8% after 12, 24, and 36 months, respec-
tively, among those assigned to rivaroxaban and 
14.7%, 24.7%, and 33.7% among those assigned 
to placebo (Fig. 2).
With regard to the three components of the 
composite primary outcome, the rates of death 
from any cause were 21.8% in the rivaroxaban 
group and 22.1% in the placebo group (hazard 
ratio, 0.98; 95% CI, 0.87 to 1.10), the rates of non-
fatal myocardial infarction were 3.9% and 4.7%, 
respectively (hazard ratio, 0.83; 95% CI, 0.63 to 
1.08), and the rates of nonfatal stroke were 2.0% 
and 3.0%, respectively (hazard ratio, 0.66; 95% CI, 
0.47 to 0.95). Across all subgroups, the findings 
were generally consistent with the overall efficacy 
result (Fig. 3, and Fig. S1 in the Supplementary 
Appendix).
Secondary Efficacy Outcomes
The composite outcome of death from cardiovas-
cular causes or rehospitalization for heart failure 
occurred in 932 patients (37.2%) in the rivaroxa-
ban group and 929 patients (36.9%) in the placebo 
group (hazard ratio, 0.99; 95% CI, 0.91 to 1.09) 
(Table 2 and Fig. 2). A total of 84.3% of the deaths 
were attributed to cardiovascular disease; death 
from cardiovascular causes occurred in 18.1% and 
18.9% of patients in the rivaroxaban and placebo 
groups, respectively (hazard ratio, 0.95; 95% CI, 
0.84 to 1.08). The rates of the composite outcome 
of death from any cause or hospitalization for 
heart failure were 39.6% and 38.7%, respectively 
(hazard ratio, 1.01; 95% CI, 0.92 to 1.10). Details 
of the other outcomes and their components are 
provided in Table 2.
Safety Outcomes
The principal safety outcome of fatal bleeding or 
bleeding into a critical space with a potential for 
causing permanent disability occurred in 18 pa-
tients (0.7%) assigned to rivaroxaban and 23 (0.9%) 
assigned to placebo (hazard ratio, 0.80; 95% CI, 
0.43 to 1.49; P = 0.48). Fatal bleeding events oc-
curred in 9 patients in each group, but fewer criti-
cal-space bleeding events occurred in the rivaroxa-
ban group than in the placebo group (13 [0.5%] 
vs. 20 [0.8%]; hazard ratio, 0.67; 95% CI, 0.33 to 
1.34; P = 0.25) (Table 2).
While taking the trial regimen, patients as-
signed to rivaroxaban had a higher risk of ISTH-
defined major bleeding than those assigned to 
placebo (3.3% vs. 2.0%; hazard ratio, 1.68; 95% CI, 
1.18 to 2.39). This result was mainly driven by the 
criterion of a decrease in hemoglobin level of at 
least 2 g per deciliter. Patients assigned to rivar-
oxaban had more bleeding events requiring hos-
pitalization than those assigned to placebo (Ta-
ble 2).
Serious adverse events were reported in 381 
patients (15.2%) assigned to rivaroxaban and 358 
patients (14.3%) assigned to placebo (Table S4 in 
the Supplementary Appendix). The percentage of 
patients who permanently discontinued the trial 
regimen because of an adverse event was 7.1% in 
the rivaroxaban group and 5.8% in the placebo 
group.
Discussion
In this trial, we tested the hypothesis that rivar-
oxaban at a dose of 2.5 mg twice daily in addition 
to standard care, in patients with recent worsening 
of chronic heart failure, reduced ejection fraction, 
and coronary artery disease who did not have 
atrial fibrillation, would be associated with a lower 
risk of the composite outcome of death from any 
cause, myocardial infarction, or stroke than pla-
cebo. In this population, rivaroxaban was not 
found to have a benefit with regard to the primary 
outcome. There was no significant between-group 
difference in the rate of the principal safety out-
come of fatal bleeding or bleeding into a critical 
space with a potential for causing permanent dis-
ability.
In patients with chronic heart failure and re-
duced ejection fraction, medical therapy directed 
at activation of neurohormonal systems and de-
vices such as cardiac resynchronization therapy 
and implantable cardioverter–defibrillators have 
had a substantial effect on the natural history.16,17 
Yet these patients remain at high long-term risk 
for death and cardiovascular events despite the 
existence of treatments that are targeted at a vari-
ety of mechanistic pathways.18-22
Early evidence suggesting a benefit of antico-
agulation in patients with heart failure was ob-
served in a previous study.23 This study was fol-
lowed by prospective clinical trials in which 
warfarin was compared with various antiplatelet 
agents,6,7 which did not show clear evidence of 
efficacy. The development of agents that modify 
the production or activity of thrombin has led to 
a growing appreciation that the hemostatic system 
may trigger inflammation, endothelial dysfunc-
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tion, and thrombosis, all of which may play a role 
in the progression of heart failure and in the 
pathogenesis of clinical events.24
Previous studies have suggested that inhibition 
of thrombin generation with rivaroxaban could be 
beneficial in patients with heart failure. In the 
Anti-Xa Therapy to Lower Cardiovascular Events 
in Addition to Standard Therapy in Subjects with 
Acute Coronary Syndrome–Thrombolysis in Myo-
cardial Infarction 51 trial (ATLAS ACS 2–TIMI 51), 
Figure 2. Kaplan–Meier Analysis of the Primary Efficacy Outcome and of Death from Cardiovascular Causes  
or Rehospitalization for Worsening Heart Failure.
The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke.
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involving patients with a recent acute coronary 
syndrome, rivaroxaban (2.5 mg twice daily) added 
to a background of dual antiplatelet therapy was 
associated with a lower likelihood of the primary 
end point of death from cardiovascular causes, 
myocardial infarction, or stroke than placebo.13 
A subgroup analysis from that trial suggested that 
patients with a history of heart failure were at a 
higher risk for cardiovascular events and derived 
greater benefit from rivaroxaban treatment.25 In 
Figure 3. Subgroup Analyses of the Primary Efficacy Outcome.
All the subgroups were prespecified. Additional subgroup analyses are provided in Figure S1 in the Supplementary Appendix. The haz-
ard ratios and 95% confidence intervals are from a Cox proportional-hazards model stratified according to region, with trial-group as-
signment as the only effect. The dashed vertical line indicates the hazard ratio in the overall trial population. For the region subgroup, 
the Cox model is unstratified. The P value (two-sided) for the interaction of trial group and each baseline subgroup is based on the Cox 
proportional-hazards model stratified according to region. The terms in the Cox model are trial group, baseline subgroup, and their in-
teraction. Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. BNP denotes brain natriuretic 
peptide, GFR glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, and NYHA New York Heart Association.
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the Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (COMPASS) trial, in 
patients with stable atherosclerotic disease, the 
combination of rivaroxaban (2.5 mg twice daily) 
plus aspirin (100 mg daily) but not rivaroxaban 
(5 mg twice daily) alone was associated with a 
significantly lower rate of the composite outcome 
of cardiovascular mortality, stroke, or myocardial 
infarction than aspirin (100 mg) alone.14 Analysis 
of the subgroup of patients with a history of heart 
failure who were enrolled in the COMPASS trial 
suggested that they may benefit from treatment 
with rivaroxaban in combination with aspirin.26
The most likely reason for the failure of riva-
roxaban at a dose of 2.5 mg twice daily to improve 
cardiovascular outcomes in the current trial is 
that thrombin-mediated events are not the major 
driver of heart failure–related events in patients 
with recent hospitalization for heart failure. In-
deed, readmission to the hospital for heart failure 
was the single most frequent event in the trial, and 
it is likely that heart failure, rather than deaths 
mediated by atherothrombotic events, contributed 
to a substantial proportion of all deaths. Wheth-
er a higher dose of rivaroxaban could have led to 
a more favorable outcome remains unknown.
This trial has some limitations. Events were 
not centrally adjudicated, and therefore we cannot 
comment on possible misclassifications of causes 
of hospitalization and death. Nonetheless, the 
systematic collection of prespecified comprehen-
sive details on events with verification of source 
data reduces the possibility of misclassification. 
Second, the rate of discontinuation of the trial 
regimen was higher than estimated. However, in-
creasing the number of events by extending fol-
low-up time allowed us to maintain the initially 
intended power of 80% to detect a significant 
effect of rivaroxaban on the primary efficacy end 
point. Third, in the absence of electrocardiograph-
ic monitoring, we cannot exclude the possibility 
that subclinical atrial fibrillation may have con-
tributed to stroke events and been favorably in-
fluenced by rivaroxaban. Finally, the rate of use of 
cardiac resynchronization therapy and implant-
able cardioverter–defibrillators was low; however, 
the rate of use of guideline-based pharmacologic 
therapy was high and was maintained through-
out the trial.
In conclusion, in patients with recent worsen-
ing of chronic heart failure and reduced ejection 
fraction who also had underlying coronary artery 
disease and were not in atrial fibrillation, low-
dose rivaroxaban added to guideline-based ther-
apy was not associated with a lower rate of the 
composite outcome of death from any cause, myo-
cardial infarction, or stroke than placebo, nor did 
it favorably influence the rate of rehospitalization 
for heart failure.
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